PP
APLT

Paloma Partners’s Applied Therapeutics APLT Stock Holding History

Paloma Partners’s Portfolio APLT Stock Details APLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-14,648
Closed -$530K – 2064
2020
Q2 		$530K Buy
+14,648
New +$613K 0.01% 1196

Other funds holding APLT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return

Paloma Partners's APLT Position: Q3 2020 in Review

Paloma Partners sold out of Applied Therapeutics (APLT) in Q3 2020, closing a stake of 14,648 shares — an estimated $530K sold.

Paloma Partners first reported a position in APLT in Q2 2020 and held it in 1 quarter. The position peaked at $530K in Q2 2020. 66 funds tracked by Wall St. Rank hold APLT as of Q3 2020.

  • Paloma Partners reported no remaining Applied Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Paloma Partners sold 14,648 Applied Therapeutics shares in Q3 2020, an estimated $530K.
  • Paloma Partners first reported a position in Applied Therapeutics in Q2 2020 and held it in 1 quarter.
  • Paloma Partners's Applied Therapeutics position peaked at $530K in Q2 2020.
  • 66 funds tracked by Wall St. Rank held Applied Therapeutics as of Q3 2020.

Based on Paloma Partners's 13F filing for Q3 2020, filed 16 Nov 2020.